Among patients with hepatitis C virus (HCV) genotype 1 or 3 infection who did not have cirrhosis, once-daily treatment with glecaprevir-pibrentasvir for either 8 weeks or 12 weeks achieved high rates of sustained virologic response. In a pair of phase 3, randomized, open-label trials, 1,208 patients with genotype 1 infection were randomly assigned 1:1 to receive once-daily glecaprevir-pibrentasvir for either 8 or 12 weeks. Patients with genotype 3 infection were randomly assisted 2:1 to receive 12 weeks of treatment with either glecaprevir-pibrentasvir or sofosbuvir-daclatasvir. Additional patients with genotype 3 infection were subsequently enrolled and nonrandomly assigned to receive 8 weeks of treatment with glecaprevir-pibrentasvir. The primary end point was the rate of sustained virologic response 12 weeks after the end of treatment. Researchers found:
- The rate of sustained virologic response at 12 weeks among genotype 1-infected patients was 99.1% in the 8-week group and 99.7% in the 12-week group.
- Genotype 3-infected patients who were treated for 12 weeks had a rate of sustained virologic response at 12 weeks of 95% with glecaprevir-pibrentasvir and 97% with sofosbuvir-daclatasvir; 8 weeks of treatment with glecaprevir-pibrentasvir had a rate of 95%.
- Adverse events were low in all treatment groups.
Zeuzem A, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018:378:354-369. doi:10.1056/NEJMoa1702417.
This Week's Must Reads
Lifestyle Behavioral Risk Factors for T2D, Diabetes Care; ePub 2018 Mar 2; Siegel, et al
Association of BMI with Lifetime Risk of CVD, JAMA Cardiol; ePub 2018 Feb 28; Khan, et al
Collaborative Care vs Usual Care in Heart Failure, JAMA Intern Med; ePub 2018 Feb 26; Bekelman, et al
Efficacy of CBT vs Education for Chronic Pain, Ann Intern Med; ePub 2018 Feb 27; Thorn, et al
Hypertension & Antihypertensive Medication Use, MMWR; 2018 Feb 23; Fang, Gillespie, et al
Must Reads in Hepatitis
Electronic Reminder Systems for HCV Screening, J Viral Hepat; ePub 2018 Feb 25; MacLean, et al
Universal HCV Screening During Pregnancy, Open Forum Infect Dis; ePub 2018 Feb 17; Boudova, et al
SVR & Risk of T2D Among Patients with HCV, J Viral Hepat; ePub 2018 Feb 25; Li, Zhang, et al
Chronic HCV Prognosis in TE-based Liver Stiffness, J Viral Hepat; ePub 2018 Jan 24; Erman, et al
Measuring HCV Intervention Success, J Viral Hepat; ePub 2018 Feb 27; Harris, et al